Teysuno (gimeracil/oteracil/tegafur)

P3, N=320, Not yet recruiting, Genfleet Therapeutics (Shanghai) Inc.

P2, N=30, Recruiting, Peking University Cancer Hospital & Institute | Not yet recruiting --> Recruiting

These findings highlight the potential of oral 5-FU derivatives as effective and safe treatment options to use after progression on CDK4/6i plus ET for patients with HR+/HER2- MBC.

P1/2, N=84, Enrolling by invitation, West China Hospital | Not yet recruiting --> Enrolling by invitation

The patient received CAPEOX regimen (capecitabine plus oxaliplatin) combined with tislelizumab therapy...Following pathological confirmation of dual primary cancers, treatment continued with the original regimen, followed by maintenance therapy with tegafur gimeracil oteracil potassium capsule (teysuno) plus tislelizumab...Through the long-term treatment course of this case, we validated the therapeutic efficacy of chemotherapy combined with immunotherapy (CAPEOX plus tislelizumab) for the rare aggressive dual primary tumors AFPGC and SCLC, demonstrating significant long-term maintenance benefits from the immunotherapy. Concurrently, this case confirmed the efficacy and safety of tislelizumab during the maintenance therapy phase for both tumors, offering a new treatment option for managing such complex clinical presentations.

Our first-in-human trial demonstrated its safety and potentially preliminary efficacy, warranting further clinical evaluation. Multiomic profiling identified specific circulating NK and T-cell subsets potentially associated with clinical outcomes, providing novel insights into the dynamic transcriptional underpinnings of the immune landscape in response to NK cell-based therapy.

We reported a case of SB-AdCC.

Although this study was a retrospective post hoc analysis of 2 phase II trials, which represents a major limitation, neoadjuvant chemotherapy with concurrent radiotherapy possibly improve survival compared with chemotherapy alone by suppressing local recurrence through a powerful local antitumor effect of radiation.

This modified approach may serve as a potential alternative to the standard GS regimen for select patients who experience intolerance to conventional therapy. A future multicenter randomized controlled study will investigate the efficacy and safety of this adjusted GS treatment strategy.

P1, N=35, Not yet recruiting, Lianyungang First People's Hospital; Lianyungang First People's Hospital

P4, N=46, Not yet recruiting, The First Affiliated Hospital of Soochow University; The First Affiliated Hospital of Soochow University

P2, N=80, Not yet recruiting, Eastern Hepatobiliary Surgical Hospital; Eastern Hepatobiliary Surgical Hospital